| HOME >> MEDICINE >> TECHNOLOGY |
FINANCIAL TABLES FOLLOW CEPHEID
CONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF OPERATIONS(in thousands, except per share data)
Three Months Ended December 31, Years Ended
December 31, 2012201120122011Revenues:System sales
$ 14,101$ 20,371$ 55,447$ 61,948Reagent and disposable sales
75,55756,576266,101203,576Total product sales
89,65876,947321,548265,524Other revenues
2,7753,1679,66412,051Total revenues
92,43380,114331,212277,575Costs and operating expenses:Cost of product sales
42,89638,632153,365122,840Collaboration profit sharing
1,4161,5827,1834,863Research and development
17,29916,65071,67359,362Sales and marketing
16,29414,49061,90750,691General and administrative
9,47010,15343,29836,004Litigation settlement
--15,110-Total costs and operating expenses
87,37581,507352,536273,760Income (loss) from operations
5,058(1,393)(21,324)3,815Other income (expense), net
241(506)(4)(1,143)Income (loss) before income taxes
5,299(1,899)(21,328)2,672Benefit from (provision for) income taxes
3452501,285(45)Net income (loss)
$
5,644$ (1,649)$ (20,043)$
2,627Basic net income (loss) per share
$
.09$
(0.03)$
(0.30)$
.04Diluted net income (loss) per share
$
.08$
(0.03)$
(0.30)$
.04Shares used in computing basic net income (loss) per share
66,37064,11365,81262,735Shares used in computing diluted net income (loss) per share
'/>"/>
| SOURCE Cepheid Copyright©2012 PR Newswire. All rights reserved |